Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PaiNT: NT 201 in Chronic Peripheral Neuropathic Pain
NCT06091020Phase 2Completed
- Sponsor
- Merz
- Start
- Nov 2023
- Primary completion
- May 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial in Peripheral neuropathic pain comparing NT 201 with Placebo (2 arms). Primary endpoint: Average Daily Pain intensity at 12 weeks. Started Nov 2023; status: completed.
02
Drugs
incobotulinumtoxinA
03
Conditions
Peripheral neuropathic pain
Beyond the preview
Go deeper on NCT06091020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06091020.